)
Edge28 Nov 2025
Keeping the Streak Alive: The Story of Duolingo
How Duolingo made language learning addictive, scaled to millions of users, and built a powerful subscription business around everyday practice.
Monte Rosa Therapeutic (GLUE) investor relations material
Monte Rosa Therapeutic Piper Sandler 37th Annual Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Piper Sandler 37th Annual Healthcare Conference summary2 Dec, 2025
Pipeline and clinical development updates
MRT-2359 targets GSPT1 for MYC-driven tumors, with Phase 1 data in prostate and breast cancer expansion arms expected by year-end, focusing on measurable disease and robust biomarker analysis.
MRT-6160, a VAV1 degrader, showed strong safety and efficacy in Phase 1, with broad development plans in partnership with Novartis targeting multiple immune-related indications.
MRT-8102 targets NEK7 in the NLRP3 inflammasome, with ongoing Phase 1 studies and a focus on cardiovascular risk reduction; preclinical data support potential in atherosclerosis and other inflammatory diseases.
IND filings for molecular glue degraders against CDK2 and cyclin E1 are planned for next year, aiming at oncology indications such as ovarian and ER-positive breast cancers.
A CNS-penetrant NEK7 degrader is in preclinical development, with IND submission targeted by the end of next year, supporting future expansion into neurodegenerative diseases.
Strategic partnerships and financial position
Novartis partnership includes VAV1 and two additional preclinical INI programs, with $120 million upfront and up to $6 billion in milestones, plus a 30% U.S. P&L share and Phase 2 milestone payments.
The company maintains a strong cash position of $390 million, with guidance through 2028, enabling aggressive development of key assets and further innovation.
Additional non-dilutive funding from partnerships is expected to further extend the cash runway and support pipeline expansion.
Platform innovation and industry outlook
The proprietary QuEEN platform leverages AI to design highly selective molecular glue degraders, enabling rapid and productive expansion of the pipeline.
The platform's productivity is evidenced by multiple clinical and preclinical assets and strong industry partnerships.
Targeted protein degradation, especially in INI and cardiovascular areas, is seen as a major growth opportunity, with future expansion into neuroscience anticipated.
Novartis's broad development plan for MRT-6160
Why is ASCVD becoming a key focus for MRT-8102?
How QuEEN platform enables monoselective degraders?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Monte Rosa Therapeutic earnings date
Q4 202520 Mar, 2026
Next Monte Rosa Therapeutic earnings date
Q4 202520 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Monte Rosa Therapeutics Inc. is a clinical-stage biotechnology company focused on developing molecular glue degraders (MGDs). These small molecules are designed to selectively degrade disease-causing proteins by harnessing the body’s natural protein degradation processes. The company targets a range of therapeutic areas, including oncology, autoimmune, and inflammatory diseases. Monte Rosa utilizes its proprietary QuEEN platform, which integrates proteomics, structural biology, AI, and machine learning, to rapidly identify and develop highly selective protein degraders. The company operates out of Boston, Massachusetts, with additional research facilities in Basel, Switzerland. Its shares trade on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage